Ozempic and Gastroparesis: What the Research Says About Timing and Risk

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Wellness to Targeted Drug Safety

If you or a loved one has developed persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be wondering if the medication could be linked to gastroparesis. For decades, pharmacovigilance systems have tracked adverse events to identify potential drug-disease associations, and recent reports have raised questions about GLP-1 receptor agonists and delayed gastric emptying. This page reviews the available evidence on the timing and risk of gastroparesis in patients using Ozempic.

Bridging to Clinical Evidence: Ozempic and Gastrointestinal Effects

Building on the transition from general wellness to specific drug safety, we now examine the clinical evidence regarding Ozempic and its gastrointestinal effects. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests, with clinical presentation varying in severity. The condition can be idiopathic or secondary to diabetes, surgery, or medications. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for glycemic control in type 2 diabetes and for weight management. Its pharmacology includes slowing gastric emptying, which contributes to its glucose-lowering effects but also raises concerns about gastrointestinal adverse effects. The prescribing information for Ozempic documents that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo, with rates of 32.7% for the 0.5 mg dose and 36.4% for the 1 mg dose, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients discontinued treatment due to gastrointestinal adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing 1 mg and 2 mg doses, gastrointestinal adverse reactions occurred in 30.8% and 34.0% of patients, respectively (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific gastrointestinal adverse reactions reported with Ozempic, with frequencies below 5%, include dyspepsia (3.5% for 0.5 mg, 2.7% for 1 mg), eructation (2.7% for 0.5 mg, 1.1% for 1 mg), flatulence (0.4% for 0.5 mg, 1.5% for 1 mg), gastroesophageal reflux disease (1.9% for 0.5 mg, 1.5% for 1 mg), and gastritis (0.8% for both doses) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as an adverse reaction in these data, the mechanistic pathway linking Ozempic to gastroparesis is plausible: GLP-1 receptor agonists delay gastric emptying, and in susceptible individuals, this effect may become pathological, leading to symptomatic gastroparesis. The label does not include a specific warning for gastroparesis, but it does caution about serious hypersensitivity reactions, including anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Risk Anchors: Adequacy of Warnings and Causation Considerations

The current prescribing information for Ozempic does not contain a specific warning for gastroparesis. The label highlights gastrointestinal adverse reactions as a class effect, with nausea, vomiting, and diarrhea being common, but does not explicitly address the risk of delayed gastric emptying leading to gastroparesis. This omission may leave patients and clinicians unaware of the potential for this serious complication, particularly in those with pre-existing gastrointestinal conditions or diabetes-related autonomic neuropathy. The absence of a dedicated warning could be considered inadequate given the mechanistic plausibility and the severity of gastroparesis. For patients who develop gastroparesis symptoms after starting Ozempic, establishing causation requires careful evaluation. Key factors include the temporal relationship between drug initiation and symptom onset, exclusion of other causes (e.g., diabetic gastroparesis, idiopathic), and consideration of dose escalation. The label notes that gastrointestinal adverse reactions are most common during dose escalation, suggesting that symptoms may emerge early in treatment. However, gastroparesis can also develop later, and its diagnosis requires objective testing. Patients with diabetes are already at increased risk for gastroparesis, complicating attribution. A thorough clinical assessment, including gastric emptying studies, is essential to differentiate drug-induced from disease-related gastroparesis. The available evidence from clinical trials indicates that gastrointestinal adverse reactions, including those that could be precursors to gastroparesis (e.g., dyspepsia, GERD), occur during the initial weeks of treatment, particularly with dose escalation. The label reports that the majority of nausea, vomiting, and diarrhea occurred during this period. However, the development of frank gastroparesis may take longer, and the label does not provide specific data on the timeline for gastroparesis as a distinct adverse event. Post-marketing reports and case series would be needed to establish a more precise timeline, but such data are not included in the provided evidence. In conclusion, while Ozempic is not explicitly labeled as causing gastroparesis, its pharmacological effect of delaying gastric emptying, combined with the high incidence of gastrointestinal adverse reactions in clinical trials, supports a mechanistic link. The absence of a specific warning for gastroparesis in the prescribing information may represent a gap in risk communication. Patients who develop persistent or severe gastrointestinal symptoms while on Ozempic should be evaluated for gastroparesis, and clinicians should consider the drug as a potential contributing factor.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Ozempic cause gastroparesis?

While Ozempic is not explicitly labeled as causing gastroparesis, its pharmacological effect of delaying gastric emptying, combined with the high incidence of gastrointestinal adverse reactions in clinical trials, supports a mechanistic link. The prescribing information reports that gastrointestinal adverse reactions occurred in 32.7% to 36.4% of patients on Ozempic versus 15.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, gastroparesis is not specifically listed as an adverse reaction, and the label does not include a dedicated warning for it.

What are the symptoms of gastroparesis?

Gastroparesis is characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy or breath tests.

How common are gastrointestinal side effects with Ozempic?

Gastrointestinal adverse reactions are common with Ozempic. In clinical trials, rates were 32.7% for the 0.5 mg dose and 36.4% for the 1 mg dose, compared to 15.3% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Nausea, vomiting, and diarrhea are the most frequent, especially during dose escalation.

Is there a warning for gastroparesis on the Ozempic label?

No, the current prescribing information for Ozempic does not contain a specific warning for gastroparesis. It highlights gastrointestinal adverse reactions as a class effect but does not explicitly address the risk of delayed gastric emptying leading to gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.